Protease Nexin-2/Amyloid β Protein Precursor

A Tight-binding Inhibitor of Coagulation Factor IXa

Alvin H. Schmaier,* Linda D. Dahl,* Annemieke J. M. Rozemuller,† Raymund A. C. Roos,‡ Steven L. Wagner,|| Raymond Chung,¹ and William E. Van Nostrand¹

*Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109-0724;

†Department of Neuropathology, Free University Hospital, 1007 MB Amsterdam, The Netherlands; ‡Department of Neurology,

Academic Hospital, 2300 RC Leiden, The Netherlands; ||Salk Institute Biotechnology/Industrial Associates, La Jolla, California 92027;

and ¹Department of Microbiology and Molecular Genetics, College of Medicine, University of California, Irvine, California 92717

Abstract

Protease nexin-2/amyloid β protein precursor (PN-2/A β PP) is an abundant, secreted platelet protein which is a potent inhibitor of coagulation Factor XIa. We examined other potential anticoagulant activities of PN-2/A β PP. Purified Kunitz protease inhibitor domain of PN-2/A β PP and PN-2/A β PP itself were found to prolong the coagulation time of plasma and pure Factor IXa. The Kunitz protease inhibitor domain also inhibited the ability of Factor IXa to activate Factor X. PN-2/A β PP inhibited Factor IXa with a K_i of 7.9 to 3.9×10^{-11} M in the absence and presence of heparin, respectively. When the second-order rate constant of PN-2/A β PP's inhibition of Factor IXa (2.7×10^8 M⁻¹min⁻¹) was compared to that of antithrombin III (3.8×10^6 M⁻¹min⁻¹), PN-2/A β PP was at least a 71-fold more potent inhibitor of Factor IXa than antithrombin III. PN-2/A β PP formed a complex with Factor IXa as detected by gel filtration and ELISA. The finding that PN-2/A β PP is a potent inhibitor of Factor IXa could help to explain the spontaneous intracerebral hemorrhages seen in patients with hereditary cerebral hemorrhage with amyloidosis Dutch-type where there is an extensive accumulation of PN-2/A β PP in their cerebral blood vessels. (*J. Clin. Invest.* 1993. 92:2540–2545.) Key words: amyloid β protein precursor • protease nexin-2 • Factor IXa • Kunitz protease inhibitor

Introduction

The amyloid β protein precursor (A β PP)¹ (1) is the parent protein to the amyloid β -protein (A β) that is deposited in se-

nile plaques and in the walls of cerebral blood vessels of patients with Alzheimer's disease (2), and patients with hereditary cerebral hemorrhage with amyloidosis Dutch-type (HCHWA-D) (3, 4). There are three major isoforms of A β PP, two of which contain a domain homologous to Kunitz-type protease inhibitors (KPI) (5). The secreted isoforms of A β PP containing the KPI domain are analogous to protease nexin-2 (PN-2) (6, 7). Although the physiologic functions of PN-2/A β PP are not yet fully understood, several studies show that PN-2/A β PP is an abundant platelet α -granule protein that is secreted upon platelet activation (8, 9) and is a potent inhibitor of intrinsic blood coagulation Factor XIa (9, 10). These findings suggest that PN-2/A β PP may function as an anticoagulant. Although Factor XI is the first protein of the hemostatic system, clinical states associated with Factor XI abnormalities are usually mild bleeding conditions that occur after trauma but are not spontaneous (11–13). If PN-2/A β PP were a physiologically important anticoagulant, it would be expected to interact with other proteins of the hemostatic system. Therefore, we sought to determine if PN-2/A β PP influences other proteins of the hemostatic system.

Methods

Proteins. PN-2/A β PP was purified from fibroblast culture media using techniques of heparin affinity chromatography and immunoaffinity chromatography as previously described (10). On nonreduced sodium dodecyl sulfate 10% polyacrylamide gel electrophoresis PN-2/A β PP is a single band at 116 kD; upon reduction, the molecular mass of the protein increased slightly. The KPI domain of PN-2/A β PP was produced in a recombinant yeast expression system and purified as previously described (14). The protease inhibitory activities of purified PN-2/A β PP and KPI domain were determined by titration with active-site titrated trypsin (10, 14). Purified human Factor IXa was purchased from Enzyme Research Laboratories (South Bend, IN). This protein on nonreduced sodium dodecyl sulfate 13% polyacrylamide gel electrophoresis showed two bands at 52 and 33 kD, and when reduced with 2% β -mercaptoethanol, four bands at 29, 25, 14, and 12 kD. This protein corrected the coagulant activity of Factor IX-deficient plasma and was detected on immunoblot with primary antibody to Factor IX. Factor IXa was also generously provided by Dr. Steven Olson, Henry Ford Hospital (Detroit, MI). Factor X was also purchased from Enzyme Research Laboratories. Antithrombin III was purchased from American Diagnostica (Greenwich, CT). The amount of antithrombin III was determined by radial immunodiffusion (Calbiochem, San Diego, CA). Human α -thrombin (3,250 U/mg) was generously provided by Dr. John Fenton, Division of Laboratories and Research, New York State Department of Health (Albany, NY).

Address correspondence to Alvin H. Schmaier, M.D., Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, 102 Observatory St., Ann Arbor, MI 48109-0724.

Received for publication 19 January 1993 and in revised form 1 June 1993.

1. Abbreviations used in this paper: A β PP, amyloid β protein precursor; A β , amyloid β protein; APTT, activated partial thromboplastin time; HCHWA-D, hereditary cerebral hemorrhage with amyloidosis Dutch type; KPI, Kunitz-type protease inhibitor; PN-2, protease nexin-2.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/93/11/2540/06 \$2.00

Volume 92, November 1993, 2540–2545

Assays. An activated partial thromboplastin time (APTT) was performed by mixing 0.05 ml plasma with 0.05 ml of a kaolin (Fisher Scientific, King of Prussia, PA) suspension (10 mg/ml) in buffer, 0.01 M Tris, 0.15 M NaCl, pH 7.4, and 0.05 ml automated APTT reagent (Organon Teknika, Research Triangle Park, NC) diluted 1:3 with buffer. After 5 min incubation at 37°C, the mixture was recalcified (0.05 ml of 30 mM CaCl₂), and the time necessary to clot formation was measured. Factors XI and IX coagulant assays were performed by mixing 0.05 ml of a 1:2 dilution of pooled normal human plasma (George King Inc., Overland Park, KS) or Factor IXa with 0.05 ml APTT reagent, 0.05 ml of a kaolin suspension, and 0.05 ml of Factor XI or IX deficient plasmas, respectively (Organon Teknika). After 5 min incubation at 37°C, the material was recalcified with 0.05 ml 30 mM CaCl₂ and the time to clot formation was measured. Plasma Factors X and VII coagulant activity were determined by mixing a 1:20 dilution of pooled normal human plasma (0.05 ml) with Factors X or VII deficient plasmas (0.05 ml) (Organon Teknika), respectively. After a 3-min incubation at 37°C, clotting was initiated by the simultaneous addition of 0.05 ml Simplastin (Organon Teknika) and 0.05 ml of 30 mM CaCl₂. Thrombin's ability to clot plasma fibrinogen was performed with 0.1 ml human α -thrombin (4 U/ml) added to 0.2 ml pooled normal plasma made 6 mM with CaCl₂.

Factor IXa enzymatic activity was measured by its ability to activate Factor X in the presence of polylysine and polyethylene glycol (15–17). Factor IXa (4.5 nM) was incubated with Factor X (400 nM) in 0.1 M triethanolamine, 0.1 M NaCl, pH 8.0 containing 0.1% polyethylene glycol (8,000 *M_r*) and 60 nM polylysine for 40 min at 20° to 25°C. At the end of the incubation, an aliquot of the activated Factor X solution was added to a solution of 0.3 mM Tosyl-Gly-Pro-Arg-*p*-nitroanilide (Sigma Chemical Co. St Louis, MO). Hydrolysis proceeded for 60 min at 20°–25°C, and the reaction was terminated by the addition of 50% acetic acid, after which the optical density reading was obtained at 405 nm. The *K_m* of Factor IXa activation of Factor X under the conditions of this assay was determined by the rate of 10–1,000 nM Factor X activation by 4.5 nM Factor IXa. These data were analyzed by double reciprocal plot. Factor IXa had no direct activity on the chromogenic substrate used in the Factor X activation assay.

Kinetics of Factor IXa inactivation. All Factor IXa used in kinetic studies was active-site titrated with antithrombin III (16). Factor IXa at an assumed concentration of 250 nM was added to various solutions containing 50–250 nM antithrombin III in 0.1 M triethanolamine, 0.1 M NaCl, pH 8.0, containing 1 U/ml heparin and 0.1% polyethylene glycol and incubated for 20 min at 20°–25°C. At the end of the incubation, aliquots were removed and added to a solution of 400 nM Factor X in 60 nM polylysine, 0.1 M triethanolamine, 0.1 M NaCl, pH 8.0 containing 0.1% polyethylene glycol and 0.3 mM Np-Tosyl-Gly-Pro-Arg-*p*-nitroanilide. After incubation for 20 min at 20°–25°C, the reaction was stopped by the addition of an equal volume of 50% acetic acid, and the samples were read at 405 nm. Assuming that the stoichiometry of Factor IXa inhibition by antithrombin III is 1:1, the antithrombin III concentration at the x-intercept of the linear regression analysis of a plot of Factor X activation versus antithrombin III concentration yielded the corresponding concentration of Factor IXa. The stoichiometry of the Factor IXa and PN-2/A β PP interaction was determined by similar means as described above for the active-site titration of Factor IXa by antithrombin III.

The equilibrium inhibition constants (*K_i*) presented for PN-2/A β PP and its KPI domain were calculated by the procedure for tight-binding inhibitors of Bieth (18) using the following equation to yield an apparent *K_i*: $K_{i,app} = \{[l/(1-a)] - E\}/(1/a)$, where *l* is the inhibitor concentration, *E* is the Factor IXa concentration, and *a* is the residual Factor IXa activity after incubation with the inhibitor. The actual *K_i* was calculated using the subsequent equation: $K_i = K_{i,app}/1 + (S/K_m)$, where *S* is the concentration of the substrate, Factor X, and *K_m* is the Michaelis constant for the Factor IXa–Factor X (protease-substrate) reaction (18). The second-order association rate constants (*K_{assoc}*) for each of the inhibitors were calculated using the integrated

second-order rate equation: $K'' = \{(1/l - E) \cdot \ln E(l - El)/l(E - El)\}/t$, where *E* is the Factor IXa concentration, *l* is the inhibitor concentration, *El* is the concentration of the enzyme-inhibitor complex, and *t* is the time of incubation in minutes (19).

Determination of complex formation between Factor IXa and PN-2/A β PP. Sephadex G-100 (Sigma) gel filtration of Factor IXa (5 μ g) or a mixture of Factor IXa (5 μ g) and PN-2/A β PP (11 μ g) was performed on a 1 $\times$ 100 cm column equilibrated in 0.01 M Tris-HCl, 0.15 M NaCl, pH 8.0. The column that was packed freshly upon each use was run on gravity at room temperature at a flow rate of 30 ml/h. Sample size was < 0.03 ml, and 1-ml fractions were collected. The void volume was determined by gel filtration of blue dextran (Sigma Chemical Co.). Molecular mass markers of human immunoglobulin G (160 kD) and bovine serum albumin (68 kD) were used to characterize the column. Column fractions were assayed for Factor IXa antigen by ELISA. 0.5 ml of each fraction was freeze dried in a concentrator (Speed-Vac; Savant Instruments, Farmingdale, NY). Each lyophilized column fraction was resuspended in 100 μ l of 0.1 M Na₂CO₃, pH 9.6, and applied to a well of a microtiter plate. After incubation overnight at 37°C, the wells were washed with 0.01 M sodium phosphate 0.15 M NaCl, pH 7.4, containing 0.05% Tween 20. After blocking the wells with 1% radioimmunoassay grade bovine serum albumin, the wells were washed again and then incubated with a goat anti-human Factor IX antibody (Enzyme Research Laboratories) diluted 1:800 followed by a rabbit anti-goat antibody conjugated with alkaline phosphatase (Sigma Chemical Co.) diluted 1:500. The color reaction was initiated by the addition of *p*-nitrophenylphosphate sodium (1 mg/ml) in 0.05 M Na₂CO₃, 1 mM MgCl, pH 9.8.

Complex formation between PN-2/A β PP and Factor IXa was also demonstrated by ELISA. Microtiter plates were coated with PN-2/A β PP (50 ng) in 0.1 M Na₂CO₃ pH 9.6 and then blocked with 1% radioimmunoassay grade bovine serum albumin (Sigma Chemical Co.). After washing, the wells were incubated with Factor IXa (20 ng) followed by a 1:800 dilution of a goat anti-human Factor IX antibody in 0.01 M sodium phosphate 0.15 M NaCl, pH 7.4 containing 0.05% Tween-20 and 10% fetal calf serum (Flow Laboratories, Springfield, VA). After further incubation and washing, a rabbit anti-goat antibody conjugated with alkaline phosphatase was added. The color reaction was initiated by the addition of *p*-nitrophenylphosphate sodium (1 mg/ml) in 0.05 M Na₂CO₃, 1 mM MgCl, pH 9.8.

Results

Initial investigations were performed to determine if a purified, recombinant KPI domain of PN-2/A β PP inhibited the coagulant activity of normal human plasma (Fig. 1 A). KPI domain at 1 μ M prolonged the APTT more than twofold over pooled normal plasma. When the ability of recombinant KPI domain to inhibit the coagulant activity of pooled normal human plasma was compared to purified whole PN-2/A β PP, which was only available at concentrations $\leq$ 200 nM, KPI domain was found to be a more potent inhibitor of the coagulant activity of plasma than PN-2/A β PP (Fig. 1 A). Since PN-2/A β PP and its KPI domain are potent inhibitors of Factor XIa, the prolongation of the APTT could simply be explained by inhibition of this enzyme alone.

To determine if the prolongation of the APTT was simply caused by the KPI domain of PN-2/A β PP inhibiting the coagulant activity of Factor XIa, specific coagulation factor assays were performed for each of the coagulation enzymes below the level of Factor XIa in the hemostatic cascade (Fig. 1 B). As previously reported for an enzymatic assay (9, 10), the KPI domain in mM concentrations had no influence on the ability of α -thrombin to clot plasma. The KPI domain at 100 μ M independently inhibited the coagulant activity of both Factors Xa and VIIa in plasma more than twofold over control.

Figure 1. Inhibition of plasma coagulation by recombinant KPI domain or purified PN-2/AβPP. (A) Pooled normal human plasma was incubated with increasing concentrations of purified recombinant KPI domain of PN-2/AβPP (1 nM–6 μM) (□) or purified PN-2/AβPP (1–200 nM) (◆) for 5 min at 37°C. At the conclusion of the incubation time, the APTT was measured (see Methods). The data represent the means of three or more experiments and are presented as fold prolongation of the clotting time over a simultaneously performed uninhibited sample. (B) The ability of the KPI domain to inhibit the coagulant activity of various specific coagulation factors in plasma was determined. Factor XIa activity (FXIa) was determined on pooled normal human plasma incubated with 1–500 nM KPI domain for 30 min at 37°C. At the conclusion of the incubation, Factor XIa coagulant activity (□) in the mixture was measured as the time necessary for clot formation. Factor IXa coagulant activity (FIXa) (◇) was determined on plasma preincubated with 1 nM–10 μM KPI domain. Factor Xa (FXa) (○) and Factor VIIa (FVIIa) (△) coagulant activities were determined on plasma preincubated with 1 nM–100 μM KPI domain. Thrombin's activity (FIIa) (●) was determined on α-thrombin (4 U/ml) preincubated with 1 nM–1 mM KPI domain for 30 min at 37°C. The data represent the means of three or more experiments and are presented as fold prolongation of the clotting time over a simultaneously performed uninhibited sample.

However, this inhibition was at least two orders of magnitude weaker than the inhibition of Factor XIa by the KPI domain, which at ~0.5 μM resulted in a twofold prolongation of the Factor XIa coagulant assay. Unexpectedly, the KPI domain of PN-2/AβPP at about 1 μM also prolonged the Factor IXa coagulant activity twofold over control. Provided that excess KPI domain was not available to inhibit the coagulant activity of

Factor XIa in this plasma, these investigations with Factor IX-deficient plasma suggested for the first time that the KPI domain of PN-2/AβPP could also be a potent inhibitor of Factor IXa.

To confirm that the KPI domain of PN-2/AβPP inhibited Factor IXa, studies were performed with pure Factor IXa. The KPI domain inhibited pure Factor IXa's (0.2 nM) ability to clot Factor IX-deficient plasma with an IC₅₀ of 70 nM (Fig. 2A). To circumvent the possibility that excess KPI domain in a coagulant assay could be inhibiting Factor XIa in the substrate plasma, an assay for Factor X activation by Factor IXa was

Figure 2. Purified recombinant KPI domain of PN-2/AβPP inhibits Factor IXa coagulant and enzymatic activities. (A) Purified Factor IXa (0.2 nM) was incubated with increasing concentrations of purified KPI domain (20 nM–10 μM) for 30 min at 37°C. At the end of the incubation, the KPI domain-treated Factor IXa was added to Factor IX-deficient plasma, and the time for clot formation was measured. The values plotted represent the percent residual coagulant activity at each concentration of KPI domain incubated with the Factor IXa when compared with an uninhibited sample. The data represent the mean±SD of three or more experiments. (B) Purified Factor IXa (4.5 nM) was incubated with increasing concentrations of purified KPI domain (20 nM to 10 μM) for 30 min at 37°C. At the end of the incubation, the KPI domain-treated Factor IXa was used to activate purified Factor X (400 nM). The values plotted represent the percent residual Factor X generating activity of the KPI domain-inhibited Factor IXa. The data represent the mean±SD of three or more experiments.

Table 1. Factor IXa Inhibition Constants

Inhibitor	K_i		K_{assoc}	
	No heparin	Heparin [‡]	No heparin	Heparin [‡]
	M		$M^{-1} \text{ min}^{-1}$	
KPI domain [‡]	$1.9 \pm 0.3 \times 10^{-7}$	—	$6.9 \pm 1.3 \times 10^5$	—
PN-2/A β PP [‡]	$7.9 \pm 1.1 \times 10^{-11}$	$3.9 \pm 1.3 \times 10^{-11}$	$2.7 \pm 0.3 \times 10^8$	$3.6 \pm 1.2 \times 10^8$

* Each inhibitor was incubated with purified Factor IXa (4.5 nM) for 5–10 min at 20–25°C. The KPI domain was used at 22.5 and 44.5 nM and PN-2/A β PP was used at 5 and 9 nM. At the end of the incubation, the inhibitor-treated Factor IXa was used to activate Factor X (400 nM) (see Methods). The data presented are the mean $\pm$ SEM of five or more experiments. [‡] Heparin was added at 1 U/ml final concentration.

established to study the effect of KPI domain on Factor IXa activity. KPI domain inhibited the ability of Factor IXa (4.5 nM) to activate Factor X (400 nM) with an IC_{50} of 280 nM (Fig. 2 B). These studies indicated that the KPI domain of PN-2/A β PP is an inhibitor of Factor IXa, as well as Factor XIa.

Both the KPI domain and PN-2/A β PP inhibited Factor IXa's ability to activate Factor X in concentrations less than 10-fold molar excess within 10 min. The stoichiometry of active-site titrated Factor IXa to PN-2/A β PP was 1.3 to 1.0. The K_m of Factor IXa activation of Factor X in this assay was 2.08 μM as determined by a double reciprocal plot. Equilibrium inhibition constants (K_i) were determined to be 7.9×10^{-11} and 3.9×10^{-11} M for the inhibition of Factor IXa by PN-2/A β PP in the absence and presence of heparin, respectively (Table I). The present findings with Factor IXa are similar to the equilibrium inhibition constants previously described for inhibition of Factor XIa by PN-2/A β PP (9, 10). Alternatively, a K_i of 1.9×10^{-7} M was obtained for the inhibition of Factor IXa by the purified KPI domain suggesting that regions outside the KPI domain may be important for optimum inhibition of Factor IXa by PN-2/A β PP. The second-order association rate constants (K_{assoc}) for Factor IXa and the KPI domain or PN-2/A β PP were determined for comparison to the K_{assoc} for Factor IXa and antithrombin III, the major plasma inhibitor of Factor IXa (20). The KPI domain itself had a K_{assoc} of $6.9 \times 10^5 \text{ M}^{-1} \text{ min}^{-1}$; however, in this assay purified PN-2/A β PP was a 400-fold faster acting inhibitor of Factor IXa with K_{assoc} of $2.7 \times 10^8 \text{ M}^{-1} \text{ min}^{-1}$ (Table I). The addition of heparin (1 U/ml) increased the rate of Factor IXa inhibition less than twofold with a K_{assoc} of $3.6 \times 10^8 \text{ M}^{-1} \text{ min}^{-1}$. PN-2/A β PP in the absence or presence of heparin was a 71-fold or 95-fold, respectively, more potent inhibitor of Factor IXa than antithrombin III in the presence of heparin ($K_{\text{assoc}} = 3.8 \times 10^6 \text{ M}^{-1} \text{ min}^{-1}$).

To confirm that PN-2/A β PP associated with Factor IXa to inactivate it, investigations were performed to determine if complex formation occurred between Factor IXa and PN-2/A β PP (Fig. 3). Purified immunoglobulin G and blue dextran (data not shown) gel filtered identically at fraction 32, characterizing the void volume of the column (Fig. 3 A). Bovine serum albumin gel filtered at fraction 38. Purified Factor IXa antigen gel filtered as a broad peak between fractions 40 and 58. This finding indicated that Factor IXa alone did not gel filter as a void volume protein on this column. When Factor IXa was incubated with purified PN-2/A β PP, a portion of the total Factor IXa antigen appeared in a new broad peak between fractions 32 and 39 (Fig. 3 B). These data indicated that some of the Factor IXa formed a higher molecular mass complex

with the purified PN-2/A β PP. Further studies were performed to determine if Factor IXa forms a complex with PN-2/A β PP as detected by ELISA (Fig. 4). When Factor IXa was incubated with PN-2/A β PP linked to microtiter plate wells, Factor IXa was detected specifically bound to the PN-2/A β PP.

Discussion

This investigation indicates that PN-2/A β PP is a newly recognized inhibitor of Factor IXa. PN-2/A β PP and its KPI domain

Figure 3. Sephadex G-100 in 0.01 M Tris, 0.15 M NaCl, pH 8.0 was used for the gel filtration of (A) Factor IXa (5 μg) alone ($\circ$) (A) or (B) a Factor IXa (5 μg) and PN-2/A β PP (11 μg) mixture ($\bullet$). The fractions where human IgG and BSA gel filtered are indicated by the arrows. The data presented represents the mean of two similar experiments.

ASSAY CONDITION

Figure 4. ELISA binding assay between PN-2/A β PP and Factor IXa. Purified PN-2/A β PP (50 ng) was linked to microtiter plate cuvette wells (see Methods). After blocking with bovine serum albumin, purified Factor IXa (20 ng), antibody to Factor IX, and a second antibody to detect the antibody to Factor IX was added in sequential order. In various wells, one of the components of the complex assay was excluded. "No APP" represents wells where no PN-2/A β PP were linked to the cuvette wells. No FIXa, wells where no Factor IXa was added; No Ab FIXa, wells where no antibody to Factor IXa were added; No 2nd Ab, wells where no second antibody to detect the anti-Factor IX antibody was added; ALL, cuvette wells where every component was added. The data presented represents the mean $\pm$ SD of 16 experiments.

inhibited Factor IXa's coagulant and enzymatic activity. The inactivation of Factor IXa was associated with complex formation between the enzyme and PN-2/A β PP. The broad peaks seen in the gel filtration experiment probably result from heterogeneity in the size of the Factor IXa used. The interaction between PN-2/A β PP and Factor IXa appears to involve more than a complex between the inhibitor and the enzyme's active site. KPI domain is a better inhibitor of plasma coagulant activity than PN-2/A β PP suggesting that various plasma proteins may modify the whole inhibitor's interaction with plasma coagulation enzymes. Alternatively, using the enzymatic assay for Factor IXa described in this study, PN-2/A β PP is a much tighter inhibitor of Factor IXa than KPI domain. These combined findings suggest that PN-2/A β PP may interact with Factor IXa at its enzymatic site and, perhaps, another region. Under the conditions of the assay performed for Factor X activation, PN-2/A β PP also appears to be a more potent inhibitor for Factor IXa than is antithrombin III, the recognized plasma inhibitor of this protein (21). Since the relative potency of an inhibitor in plasma can be determined by multiplying its K_{assoc} by the inhibitor's plasma concentration and comparing this value with other known inhibitors (22), antithrombin III, which has a plasma concentration of 2.7 μ M (20), must account for 99% of the plasma inhibition of Factor IXa since the normal plasma concentration of PN-2/A β PP is only 60 pM (23). However, large amounts of PN-2/A β PP are secreted by activated platelets (8, 9), an event that occurs in parallel to coagulation at sites of vascular damage. If physiologically signif-

icant activation of Factor IX occurs on endothelial cell and platelet surfaces (24, 25), then PN-2/A β PP, a cell surface-associated protein, would be the most potent regulator of Factor IXa at this locus. This new property of PN-2/A β PP to inhibit Factor IXa, coupled with its potent inhibition of Factor XIa, strongly suggests that PN-2/A β PP influences the initiation of hemostatic reactions.

The importance of Factor IX in hemostasis is underscored by the finding that individuals with a deficiency in this protein have spontaneous bleeding states of whom 12% have intracerebral hemorrhage (26, 27). The finding that PN-2/A β PP is an inhibitor of Factor IXa may be important in understanding the pathogenesis of HCHWA-D. HCHWA-D, a rare disorder that is associated with recurrent and often fatal spontaneous intracerebral hemorrhages in midlife (3, 4), results from a point mutation in the A β PP gene that substitutes glutamine for glutamic acid at residue 22 in the A β domain (28, 29). It has been postulated that this mutation contributes to the pathologic liberation of A β and its deposition in the brain parenchyma and in the cerebral blood vessels of patients with this disorder. In addition to A β deposition, immunohistochemical staining investigations showed that HCHWA-D patients also exhibited extensive deposits of PN-2/A β PP in their cerebral vessels (30). The selective accumulation of PN-2/A β PP in the cerebral vessels of HCHWA-D patients could result in decreased Factor IXa activity, leading to the spontaneous intracerebral hemorrhages characteristic of this disorder (3, 4).

Acknowledgments

We appreciate the technical assistance of Ms. Fakhri Mahdi, the helpful discussions about this work with Drs. Guy Salvassen and Steve T. Olson, and the critical reviews by Drs. Dennis Cunningham and Steve Weiss. This work was supported in part by a grant from the American Health Assistance Foundation (W. E. Van Nostrand and A. H. Schmaier), National Institutes of Health grants HL-35553, HL-01615, HL-45486 (A. H. Schmaier), and as well as AG00538 (W. E. Van Nostrand) and HL-49566 (W. E. Van Nostrand and A. H. Schmaier).

References

1. Kang, J., H. G. Lemaire, A. Unterbeck, J. M. Salbaum, C. L. Masters, K. H. Grzesick, G. Multhaup, K. Beyreuther, and B. Muller-Hill. 1987. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature (Lond.)*. 325:733-736.
2. Glenner, G. G., and C. W. Wong. 1984. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. *Biochem. Biophys. Res. Commun.* 120:885-890.
3. Luyendijk, W., G. T. Bots, M. Vegter-van der Vlis, L. N. Went, and B. Frangione. 1988. Hereditary cerebral hemorrhage caused by cortical amyloid angiopathy. *J. Neurol. Sci.* 85:267-280.
4. Van Duinen, S. G., E. M. Castano, F. Prelli, G. T. Bots, W. Luyendijk, and B. Frangione. 1987. Hereditary cerebral hemorrhage with amyloidosis in patients of Dutch origin is related to Alzheimer disease. *Proc. Natl. Acad. Sci. USA*. 84:5991-5994.
5. Ponte, P., P. Gonzalez-Dewhitt, J. Schilling, J. Miller, D. Hsu, B. Greenburg, K. Davis, W. Wallace, I. Lieberburg, and F. Fuller. 1988. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. *Nature (Lond.)*. 331:525-527.
6. Van Nostrand, W. E., S. L. Wagner, M. Suzuki, B. H. Choi, J. S. Farrow, J. W. Geddes, C. W. Cotman, and D. D. Cunningham. 1989. Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. *Nature (Lond.)*. 341:546-549.
7. Oltersdorf, T., L. C. Fritz, D. B. Schenk, I. Lieberburg, K. L. Johnson-Wood, E. C. Beattie, P. J. Ward, R. W. Blacher, H. F. Dovey, and S. Sinha. 1989. The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II. *Nature (Lond.)*. 341:144-147.
8. Van Nostrand, W. E., A. H. Schmaier, J. S. Farrow, and D. D. Cun-

- ningham. 1990. Protease nexin-II (Amyloid β -protein precursor): a platelet α -granule protein. *Science (Wash. DC)*. 248:745-748.
9. Smith, R. P., D. A. Higuchi, and G. J. Broze, Jr. 1990. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. *Science (Wash. DC)*. 248:1126-1128.
10. Van Nostrand, W. E., S. L. Wagner, J. S. Farrow, and D. D. Cunningham. 1990. Immunopurification and protease inhibitory properties of protease nexin-2/amyloid beta-protein precursor. *J. Biol. Chem.* 265:9591-9594.
11. Rapaport, S. I., R. R. Proctor, M. J. Patch, and M. Yettra. 1961. The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. *Blood*. 18:149-165.
12. Seligsohn, U. 1978. High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. *Blood*. 51:1223-1228.
13. Bolton-Maggs, P. H. B., B. Young-Wan-Yin, A. H. McCraw, J. Slack, and P. B. A. Kernoff. 1988. Inheritance and bleeding in factor XI deficiency. *Br. J. Haematol.* 69:521-528.
14. Wagner, S. L., R. S. Siegel, T. S. Vedvick, W. C. Raschke, and W. E. Van Nostrand. 1992. High level expression, purification, and characterization of the Kunitz-type protease inhibitor domain of protease nexin-2/amyloid beta-protein precursor. *Biochem. Biophys. Res. Commun.* 186:1138-1145.
15. Lundblad, R. L., and H. R. Roberts. 1982. The acceleration by polylysine of the activation of factor X by factor IXa. *Thromb. Res.* 25:319-329.
16. Griffin, M. J., L. Breikreutz, H. Trapp, E. Briet, C. M. Noyes, R. L. Lundblad, and H. R. Roberts. 1985. Characterization of the clotting activities of structurally different forms of activated Factor IX. *J. Clin. Invest.* 75:4-10.
17. McCord, D. M., D. M. Monroe, K. J. Smith, and H. R. Roberts. 1990. Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain. *J. Biol. Chem.* 265:10250-10254.
18. Bieth, J. G. 1984. In vivo significance of kinetic constants of protein proteinase inhibitors. *Biochem. Med.* 32:387-397.
19. Gigli, I., J. W. Mason, R. W. Colman, and F. W. Austin. 1970. Interaction of plasma kallikrein with the C1 inhibitor. *J. Immunol.* 104:574-581.
20. Harpel, P. 1987. Proteolytic enzyme inhibitors: their role in modulating blood coagulation and fibrinolytic enzyme pathways. In *Hemostasis and Thrombosis*. 2nd ed. R. W. Colman, J. Hirsh, V. J. Marder, and E. W. Salzman, editors. J. B. Lippincott, Philadelphia, PA. pp. 219-234.
21. Rosenberg, J. S., P. W. McKenna, and R. D. Rosenberg. 1975. Inhibition of human factor IXa by human antithrombin. *J. Biol. Chem.* 250:8883-8888.
22. Scott, C. F., M. Schapira, H. L. James, A. B. Cohen, and R. W. Colman. 1982. Inactivation of Factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen. *J. Clin. Invest.* 69:844-852.
23. Van Nostrand, W. E., A. H. Schmaier, J. S. Farrow, D. B. Cines, and D. D. Cunningham. 1991. Protease nexin-2/amyloid beta-protein precursor in blood is a platelet-specific protein. *Biochem. Biophys. Res. Commun.* 175:15-21.
24. Stern, D. M., M. Drillings, W. Kiesel, P. Nawroth, H. L. Nessel, and K. S. LaGamma. 1984. Activation of factor IX bound to cultured bovine aortic endothelial cells. *Proc. Natl. Acad. Sci. USA*. 81:913-917.
25. Ahmad, S. S., R. Rawala-Sheikh, and P. N. Walsh. 1989. Comparative interactions of factor IX and factor IXa with human platelets. *J. Biol. Chem.* 264:3244-3251.
26. Biggs, R. 1977. Haemophilia treatment in the United Kingdom from 1969 to 1974. *Br. J. Haematol.* 35:487-504.
27. Levine, P. 1987. Clinical manifestations and therapy of hemophilias A and B. In *Hemostasis and Thrombosis*. R. W. Colman, J. Hirsh, V. J. Marder, and E. W. Salzman, editors. J. B. Lippincott, Philadelphia, PA. pp. 97-111.
28. Van Broeckhoven, C., J. Haan, E. Bakker, J. A. Hardy, W. Van Hul, A. Wehnert, M. Vegter-van der Vliet, and R. A. C. Roos. 1990. Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis. *Science (Wash. DC)*. 248:1120-1122.
29. Levy, E., M. D. Carman, I. J. Fernandez-Madrid, M. D. Power, I. Lieberburg, S. G. Van Duinen, G. T. Bots, W. Luyendijk, and B. Frangione. 1990. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage Dutch type. *Science (Wash. DC)*. 248:1124-1126.
30. Rozemuller, A. J. M., R. A. C. Roos, G. T. A. M. Bots, W. Kamphorst, P. Eikelenboom, and W. E. Van Nostrand. 1993. Distribution of β /A4 protein and amyloid precursor protein in hereditary cerebral hemorrhage with amyloidosis-Dutch type and Alzheimer's Disease. *Am. J. Pathol.* 142:1449-1457.